United Health Products Faces FDA Hurdle in Medical Device Approval Process

United Health Products (OTCQB: UEEC) has been approved for uplisting to the OTCQB Venture Market, marking a significant milestone in the company's corporate development strategy. Simultaneously, the company is addressing regulatory challenges with the Food and Drug Administration regarding its CelluSTAT Hemostatic Gauze product.

The OTCQB uplisting represents an opportunity for increased investor visibility and improved stock liquidity. CEO Brian Thom emphasized the move as a demonstration of the company's commitment to corporate transparency and investor engagement.

However, the company faces a potential setback in its clinical development process. The FDA has declined to approve the Investigational Device Exemption (IDE) application for a follow-on clinical study. The decision stems from findings in Bioresearch Monitoring audits of UHP's 2019 clinical study, despite no specific deficiencies being cited in the current study design.

UHP is proactively scheduling a teleconference with FDA representatives within the next 10 days, hoping to resolve the outstanding issues and proceed with its clinical study. The company continues to advance preparatory tasks while awaiting IDE approval.

The ongoing regulatory process underscores the complex journey medical technology companies navigate in bringing innovative products to market. UHP's CelluSTAT Hemostatic Gauze, an all-natural product designed to control mild to moderate bleeding, remains a key focus of the company's strategic objectives.

While the FDA has not rejected the product outright, the current pause in the approval process highlights the rigorous standards medical device manufacturers must meet. Investors and industry observers will likely watch closely as UHP works to address the FDA's concerns and advance its Premarket Approval application.